Champignon Brands Announces Contract Research Partner For Ketamine, Psilocybin IP Portfolio
Champignon Brands (CSE: SHRM) announced this morning that it is advancing its drug discovery program with the selection of Dalriada as the firms contract research organization. Dalriada will advance Champignon’s new chemical entity IP portfolio in the areas of ketamine and psilocybin molecular scaffolds.
The partnership with Dalriada is expected to bring a robust pipeline of preclinical and clinical assets to Champignon, with Dalriada also providing integrated research and development support to the firm. The announcement of the contract research organization is anticipated to accelerate existing preclinical assets as well as the currently ongoing development of proprietary delivery systems.
Daldriada is a contract research organization that provides provides a suite of services in the area of drug discovery, medicinal chemistry, and IP for lean biotech clients that are focused on developing small molecule therapies. The firms research and development operations are located in Mississauga, Ontario.
Champignon Brands last traded at $1.22 on the CSE.
FULL DISCLOSURE: Champignon Brands is a client of Canacom Group, the parent company of The Deep Dive. The author has been compensated to cover Champignon Brands on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.
As the founder of The Deep Dive, Jay is focused on all aspects of the firm. This includes operations, as well as acting as the primary writer for The Deep Dive’s stock analysis. In addition to The Deep Dive, Jay performs freelance writing for a number of firms and has been published on Stockhouse.com and CannaInvestor Magazine among others.
